Ani Pharmaceuticals (ANIP) Convertible Debt (2010 - 2026)

Ani Pharmaceuticals has disclosed Convertible Debt across 12 years of filings, most recently posting $309.0 million for Q2 2026.

• In Q2 2026, Convertible Debt rose 0.7% year-over-year to $309.0 million; the TTM figure through Jun 2026 stood at $309.0 million (up 0.7% YoY), while the FY2025 annual figure was $307.9 million, up 0.69% from the prior year.
• Convertible Debt came in at $309.0 million for Q2 2026 at Ani Pharmaceuticals, roughly flat from $308.5 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $309.0 million in Q2 2026 to a low of $305.3 million in Q3 2024.
• Average Convertible Debt over 3 years is $307.1 million, with a median of $307.1 million recorded in 2025.
• Year-over-year, Convertible Debt increased 0.69% in 2025 and climbed 0.7% in 2026.
• Over 3 years, Convertible Debt stood at $305.8 million in 2024, then climbed by 0.69% to $307.9 million in 2025, then increased by 0.35% to $309.0 million in 2026.
• Per Business Quant data, the three most recent Convertible Debt figures were $309.0 million in Q2 2026, $308.5 million in Q1 2026, and $307.9 million in Q4 2025.